Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2022-06-10 AGM Information
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting
AGM Information Classification · 1% confidence The document explicitly states it is an announcement regarding the results of the 'ordinary annual and extraordinary general meeting' held on June 9, 2022. This directly relates to shareholder meetings and the outcomes thereof. The definition for AGM Information (AGM-R) covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. While this is the *results* announcement rather than the presentation itself, the core subject matter is the AGM. Furthermore, the document mentions the approval of financial statements and compensation policy, which are typical AGM outcomes. Since the document is a news release announcing the results, and not the detailed voting results (DVA) or the proxy materials (PSI), AGM-R is the most appropriate fit for general AGM outcome reporting, especially when the text focuses on the meeting itself.
2022-06-10 English
Abivax publie les résultats de l’étude de phase 2a d’obefazimod (ABX464) dans la PR dans la revue scientifique « Annals of the Rheumatic Diseases » et assurera une présentation lors de l’EULAR 2022
Earnings Release Classification · 1% confidence The document is a press release dated June 1, 2022, announcing that Abivax has published the Phase 2a study results for its drug obefazimod (ABX464) in Rheumatoid Arthritis in the scientific journal 'Annals of the Rheumatic Diseases' (ARD) and that a presentation will be given at EULAR 2022. The text details clinical results (efficacy and safety) and mentions the drug's new International Nonproprietary Name (INN). This format—a formal announcement of scientific data publication and presentation, often including quotes from management and investigators—is characteristic of an Earnings Release (ER) or a general press release detailing significant operational/clinical milestones. Since it is not a full financial report (10-K/IR) or a transcript (CT), and it focuses on releasing key results/updates, 'ER' (Earnings Release) is the closest fit among the options for a major, time-sensitive operational announcement, although 'RNS' (Regulatory Filings) is also plausible as a general announcement. Given the focus on announcing key results and scientific validation, ER is selected as the primary category for significant clinical/operational news releases, especially since it is not a short announcement merely pointing to an attached report (Menu vs Meal rule does not strictly apply here as the content is the announcement itself, not just a pointer). FY 2022
2022-06-01 French
Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal Annals of the Rheumatic Diseases and selected for presentation at EULAR 2022
Regulatory Filings Classification · 1% confidence The document is a press release dated June 1, 2022, announcing that phase 2a study results for the drug obefazimod (ABX464) in rheumatoid arthritis have been published in the journal 'Annals of the Rheumatic Diseases' (ARD) and selected for presentation at EULAR 2022. It details clinical trial outcomes, safety profiles, and management commentary. This is not a formal regulatory filing like a 10-K or an IR, nor is it a general announcement of a report publication (RPA) as it contains substantial, detailed scientific and clinical information. It is a specific announcement of scientific/clinical data dissemination. Since there is no specific category for 'Clinical Trial Result Announcement' or 'Scientific Publication Announcement', and it is a detailed corporate news release about clinical progress, it best fits the general 'Regulatory Filings' (RNS) category as a fallback for significant corporate news that isn't covered by the other specific financial/governance codes. However, given the content is focused on clinical study results and publication, it is a form of Investor Relations material. Comparing the options, it is not an Earnings Release (ER), Interim Report (IR), or Management Discussion (MDA). It is a detailed update on drug development, which often falls under general investor communication. Given the options, RNS is the most appropriate general category for detailed, non-standardized corporate news releases, although 'IP' (Investor Presentation) or 'LTR' (Legal/Regulatory update, loosely applied to clinical trial news) could be considered. Sticking to the provided definitions, this is a detailed corporate news release about study results, which is often categorized as RNS when specific scientific/clinical codes are absent.
2022-06-01 English
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.22.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated May 24, 2022, titled 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references compliance with French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16), detailing the theoretical and exercisable voting rights as of April 30, 2022. This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure changes or general compliance updates. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it deals specifically with the structure of voting rights and share count, it fits best under the general regulatory announcement category, which is RNS, as it is a specific compliance disclosure that doesn't map perfectly to the other specialized codes like DVA (which is for *results* of a vote, not the current count) or SHA (which is for *changes* like splits/issues, though related). Given the context of mandatory disclosure of share/voting counts under AMF rules, RNS (Regulatory Filings) is the most appropriate general classification for this specific compliance notice.
2022-05-24 French
Abivax annonce son assemblée générale mixte le 9 juin 2022 et la mise à disposition des documents préparatoires
Report Publication Announcement Classification · 1% confidence The document is titled "ABIVAX ANNONCE SON ASSEMBLEE GENERALE MIXTE LE 9 JUIN 2022 ET LA MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES" (ABIVAX ANNOUNCES ITS COMBINED GENERAL MEETING ON JUNE 9, 2022 AND THE AVAILABILITY OF PREPARATORY DOCUMENTS). This explicitly announces a General Meeting (Assemblée Générale). The text states that the preparatory documents are made available to shareholders. Since the document is short (2551 chars) and its primary function is to announce the meeting date and the availability of related materials, it fits the description of an announcement related to the AGM, but more specifically, it is announcing the meeting itself and the associated documentation availability. The closest specific code is AGM-R (AGM Information), which covers presentations and materials shared during the AGM. However, given the structure—announcing the meeting date and stating documents are available—it strongly aligns with the intent of notifying stakeholders about the upcoming AGM event and related materials, which is often covered by AGM-R or sometimes RPA if it were purely about the publication of a report. Since it is about the meeting itself, AGM-R is the most appropriate classification for the event announcement.
2022-05-18 French
ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
AGM Information Classification · 1% confidence The document explicitly announces the date and details for the company's 'annual ordinary and extraordinary general meeting' (AGM) and mentions the availability of preparatory documents. The keyword 'AGM/EGM' is present in the metadata section. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions the availability of documents, the primary focus is the announcement of the meeting itself, making AGM-R a better fit than RPA, as the content is about the meeting logistics rather than just the publication of a separate report.
2022-05-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.